...
【24h】

Boom and Bust for Homocysteine?

机译:同型半胱氨酸的繁荣与萧条?

获取原文
获取原文并翻译 | 示例

摘要

Just a few short years ago, elevated homocysteine levels were widely considered to be a risk factor for a plethora of diseases from cardiovascular disorders to neurodegenerative conditions. Because of this there was a boom in research into this amino acid, with over 13 000 scientific papers published on it by January, 2008. It was hoped that simple pharmacological and dietary intervention to lower plasma homocysteine would offer a cost-effective solution to prevent the future development of disease in individuals with high homocysteine levels. However, trials of vitamin therapies to counteract elevated homocysteine, whilst successful in lowering plasma homocysteine, have not demonstrated any clinical benefit. Thus, many now believe that it is possible that elevated homocysteine levels are a consequence of, rather than a cause of, cardiovascular and neurodegenerative disorders. If this is so, then the value of homocysteine as a target for research and pharmacological intervention is greatly reduced. So, is the boom time for homocysteine research over? This review will consider the scientific studies relating to homocysteine and neurodegenerative conditions, with particular reference to Alzheimer's Disease and Parkinson's Disease, and will consider what is next for homocysteine research.
机译:就在短短几年前,高半胱氨酸水平被广泛认为是从心血管疾病到神经退行性疾病等多种疾病的危险因素。因此,对该氨基酸的研究迅速发展,到2008年1月发表了13 000多篇科学论文。人们希望通过简单的药理和饮食干预降低血浆高半胱氨酸的含量,能够为预防这种氨基酸提供一种经济有效的解决方案。高半胱氨酸水平个体的疾病未来发展。然而,尽管维生素疗法能够成功地降低血浆高半胱氨酸水平,但可以抵消高半胱氨酸水平升高的维生素疗法的试验并未显示出任何临床益处。因此,现在许多人认为高半胱氨酸水平升高可能是心血管和神经退行性疾病的结果,而不是原因。如果是这样,那么同型半胱氨酸作为研究和药理干预目标的价值将大大降低。那么,高半胱氨酸研究的繁荣时期是否结束了?这篇综述将考虑与高半胱氨酸和神经退行性疾病有关的科学研究,特别是针对阿尔茨海默氏病和帕金森氏病的研究,并将考虑下一步对高半胱氨酸的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号